Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 5
1992 3
1995 2
1996 4
1997 7
1998 10
1999 14
2000 5
2001 9
2002 11
2003 9
2004 18
2005 15
2006 24
2007 11
2008 8
2009 14
2010 5
2011 7
2012 12
2013 21
2014 14
2015 17
2016 19
2017 13
2018 13
2019 15
2020 13
2021 13
2022 13
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B, Chai-Adisaksopha C, Garcia D. Samuelson B, et al. J Thromb Thrombolysis. 2015 Nov;40(4):474-9. doi: 10.1007/s11239-015-1218-2. J Thromb Thrombolysis. 2015. PMID: 25894476 Review.
Cytoreductive therapy, with or without low-dose aspirin, is the mainstay of thrombotic risk reduction in patients with essential thrombocythemia (ET), but the optimal choice of agent remains unclear. ...A literature search for randomized, controlled trials comparing …
Cytoreductive therapy, with or without low-dose aspirin, is the mainstay of thrombotic risk reduction in patients with essential t …
Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population.
Bieniaszewska M, Sobieralski P, Leszczyńska A, Dutka M. Bieniaszewska M, et al. Leuk Res. 2022 Dec;123:106962. doi: 10.1016/j.leukres.2022.106962. Epub 2022 Sep 21. Leuk Res. 2022. PMID: 36183610 Free article.
According to the current treatment recommendations, anagrelide, an oral antiplatelet agent, is recommended as a second-line therapy for patients with high-risk essential thrombocythemia experiencing intolerance or refractoriness to first-line approach, such a …
According to the current treatment recommendations, anagrelide, an oral antiplatelet agent, is recommended as a second-line therapy f …
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Birgegård G. Birgegård G. Curr Hematol Malig Rep. 2016 Oct;11(5):348-55. doi: 10.1007/s11899-016-0335-0. Curr Hematol Malig Rep. 2016. PMID: 27497846 Free PMC article. Review.
Anagrelide (ANA) is a drug with specific platelet-lowering activity, used primarily in ET, registered as a second-line drug in essential thrombocythemia (ET) in Europe and in some countries as first-line therapy, in USA licensed by FDA for thrombocythemia …
Anagrelide (ANA) is a drug with specific platelet-lowering activity, used primarily in ET, registered as a second-line drug in ess …
Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review.
Sugawara M, Okada S, Kanda M, Iseki T, Sakaida E, Kobayashi Y. Sugawara M, et al. Intern Med. 2022 Nov 1;61(21):3293-3299. doi: 10.2169/internalmedicine.9090-21. Epub 2022 Mar 26. Intern Med. 2022. PMID: 35342135 Free PMC article. Review.
Anagrelide is used worldwide to treat essential thrombocythemia (ET) by reducing platelet counts. ...A 46-year-old, otherwise healthy, Japanese ET patient developed HF with reduced ejection fraction after 18 months of treatment with 1.0-3.5 mg of anagrelid …
Anagrelide is used worldwide to treat essential thrombocythemia (ET) by reducing platelet counts. ...A 46-year-old, oth …
Essential thrombocythemia.
Finazzi G, Harrison C. Finazzi G, et al. Semin Hematol. 2005 Oct;42(4):230-8. doi: 10.1053/j.seminhematol.2005.05.022. Semin Hematol. 2005. PMID: 16210036 Review.
Significant progress in our understanding of the molecular pathogenesis of essential thrombocythemia (ET) and the other Philadelphia (Ph) chromosome-negative myeloproliferative disorders (MPDs) has recently been achieved. ...Myelosuppressive agents are not recommend …
Significant progress in our understanding of the molecular pathogenesis of essential thrombocythemia (ET) and the other Philad …
Anagrelide-induced pericardial effusion in a patient with essential thrombocythemia.
Song D, Shabani J, Jaiswal V, Paudel K, Gupta A, Rubinstein D. Song D, et al. Clin Case Rep. 2023 Apr 23;11(4):e7246. doi: 10.1002/ccr3.7246. eCollection 2023 Apr. Clin Case Rep. 2023. PMID: 37102091 Free PMC article.
In patients with comorbid conditions, this can prove to be a challenge in its co-management along with the primary disease. We present a rare case of anagrelide-induced pericardial effusion that is presented with tamponade physiology in a patient with essential t …
In patients with comorbid conditions, this can prove to be a challenge in its co-management along with the primary disease. We present a rar …
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA. Verstovsek S, et al. Future Oncol. 2022 Sep;18(27):2999-3009. doi: 10.2217/fon-2022-0596. Epub 2022 Aug 4. Future Oncol. 2022. PMID: 35924546 Free article.
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source. ...SURPASS-ET (NCT04285086) is a phase III, open-label, mult …
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombos …
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
Mazzucconi MG, Baldacci E, Latagliata R, Breccia M, Paoloni F, Di Veroli A, Cedrone M, Anaclerico B, Villivà N, Porrini R, Montefusco E, Andriani A, Montanaro M, Scaramucci L, Spadea A, Rago A, Cimino G, Spirito F, Santoro C. Mazzucconi MG, et al. Eur J Haematol. 2020 Sep;105(3):335-343. doi: 10.1111/ejh.13454. Epub 2020 Jun 16. Eur J Haematol. 2020. PMID: 32441419
BACKGROUND AND AIMS: Anagrelide is a drug effective in reducing platelet counts in essential thrombocythemia (ET) and Ph1-negative myeloproliferative neoplasms. ...RESULTS: One hundred and fifty patients received anagrelide for a median time of 7.4 yea …
BACKGROUND AND AIMS: Anagrelide is a drug effective in reducing platelet counts in essential thrombocythemia (ET) and P …
Essential thrombocythemia.
Brière JB. Brière JB. Orphanet J Rare Dis. 2007 Jan 8;2:3. doi: 10.1186/1750-1172-2-3. Orphanet J Rare Dis. 2007. PMID: 17210076 Free PMC article. Review.
Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. ...The therapeutic value of hydroxycarbamide and aspirin in high risk patients ha …
Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of plat …
A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Dingli D, Tefferi A. Dingli D, et al. Leuk Lymphoma. 2005 May;46(5):641-50. doi: 10.1080/10428190400029817. Leuk Lymphoma. 2005. PMID: 16019501 Review.
In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in high-risk patients with essential thrombocythemia (ET). Despite the absence of similar evidence for clinical benefit, the platel …
In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in hi …
326 results